A Phase II Study of the HSP90 Inhibitor AUY922 in Patients With Relapsed and Refractory Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Luminespib (Primary)
- Indications Diffuse large B cell lymphoma; Peripheral T-cell lymphoma
- Focus Therapeutic Use
- 28 Nov 2016 Status changed from completed to discontinued.
- 25 Jun 2015 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017 as per ClinicalTrials.gov record.
- 19 Jun 2014 Status changed from active, no longer recruiting to completed as reported by M.D. Anderson cancer centre.